<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font32 { font-size : 32; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font22 { font-size : 22; } .font23 { font-size : 23; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font32">days </span>
   <span class="font30">fremanezumab </span>
   <span class="font23">CGRP </span>
   <span class="font23">patients </span>
   <span class="font23">migraine </span>
   <span class="font22">Phase </span>
   <span class="font22">monthly </span>
   <span class="font20">treatment </span>
   <span class="font20">{border-style </span>
   <span class="font19">headache </span>
   <span class="font19">px;} </span>
   <span class="font19">quarterly </span>
   <span class="font18">#ffffff;} </span>
   <span class="font18">weeks </span>
   <span class="font18">monoclonal </span>
   <span class="font17">Headache </span>
   <span class="font17">dose </span>
   <span class="font17">reported </span>
   <span class="font17">site </span>
   <span class="font16">placebo </span>
   <span class="font16">Bigal </span>
   <span class="font16">Fremanezumab </span>
   <span class="font16">adverse </span>
   <span class="font16">compared </span>
   <span class="font16">events </span>
   <span class="font16">preventive </span>
   <span class="font16">study </span>
   <span class="font15">baseline </span>
   <span class="font15">chronic </span>
   <span class="font15">episodic </span>
   <span class="font15">antibody </span>
   <span class="font15">data </span>
   <span class="font15">medication </span>
   <span class="font15">reduced </span>
   <span class="font14">III </span>
   <span class="font14">fremanezumab, </span>
   <span class="font14">injection </span>
   <span class="font14">reduction </span>
   <span class="font14">use </span>
   <span class="font14">Dodick </span>
   <span class="font14">effects </span>
   <span class="font14">peptide </span>
   <span class="font14">px; </span>
   <span class="font14">trials </span>
   <span class="font14">{font-family </span>
   <span class="font13">MMD </span>
   <span class="font13">VanderPluym </span>
   <span class="font13">antibodies </span>
   <span class="font13">cluster </span>
   <span class="font13">days. </span>
   <span class="font13">effect </span>
   <span class="font13">efficacy </span>
   <span class="font13">font-size </span>
   <span class="font13">months </span>
   <span class="font13">new </span>
   <span class="font13">patient </span>
   <span class="font13">placebo. </span>
   <span class="font13">showed </span>
   <span class="font13">time </span>
   <span class="font13">trial </span>
   <span class="font13">American </span>
   <span class="font13">doses </span>
   <span class="font13">dosing, </span>
   <span class="font13">double; </span>
   <span class="font13">including </span>
   <span class="font13">migraine: </span>
   <span class="font13">randomized </span>
   <span class="font13">risk </span>
   <span class="font13">safety </span>
   <span class="font13">significant </span>
   <span class="font13">studies </span>
   <span class="font12">(CGRP) </span>
   <span class="font12">Cephalalgia </span>
   <span class="font12">IIb </span>
   <span class="font12">Injection </span>
   <span class="font12">Placebo: </span>
   <span class="font12">Safety </span>
   <span class="font12">TEV- </span>
   <span class="font12">border-color </span>
   <span class="font12">border-width </span>
   <span class="font12">clinical </span>
   <span class="font12">common </span>
   <span class="font12">controlled </span>
   <span class="font12">days, </span>
   <span class="font12">decreased </span>
   <span class="font12">dosing </span>
   <span class="font12">drug </span>
   <span class="font12">gene-related </span>
   <span class="font12">high </span>
   <span class="font12">increased </span>
   <span class="font12">long-term </span>
   <span class="font12">primary </span>
   <span class="font12">reaction </span>
   <span class="font12">related </span>
   <span class="font12">solid; </span>
   <span class="font12">studied </span>
   <span class="font12">subcutaneous </span>
   <span class="font12">work </span>
   <span class="font12">{font-style </span>
   <span class="font12">{font-weight </span>
   <span class="font12">./head. </span>
   <span class="font12">Neurology </span>
   <span class="font12">OLE </span>
   <span class="font12">Pain </span>
   <span class="font12">Placebo </span>
   <span class="font12">Post-hoc </span>
   <span class="font12">Robblee </span>
   <span class="font12">Society </span>
   <span class="font12">Teva </span>
   <span class="font12">acute </span>
   <span class="font12">benefit </span>
   <span class="font12">bold </span>
   <span class="font12">calcitonin </span>
   <span class="font12">cases </span>
   <span class="font12">change </span>
   <span class="font12">courier; </span>
   <span class="font12">demonstrated </span>
   <span class="font12">double-blind, </span>
   <span class="font12">em; </span>
   <span class="font12">endpoint </span>
   <span class="font12">fremanezumab. </span>
   <span class="font12">loading </span>
   <span class="font12">mg: </span>
   <span class="font12">migraine. </span>
   <span class="font12">p&amp;lt;.). </span>
   <span class="font12">phase </span>
   <span class="font12">placebo), </span>
   <span class="font12">post-traumatic </span>
   <span class="font12">prophylactic </span>
   <span class="font12">pt;} </span>
   <span class="font12">question </span>
   <span class="font12">raised </span>
   <span class="font12">reports </span>
   <span class="font12">review </span>
  </p>
 </body>
</html>
